Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
U.S. Dial-in Number: 833-634-2546
International Dial-in Number: 412-902-4190
All participants should ask to be connected to the Fulcrum Therapeutics conference call.
Replay U.S. Dial-in Number: 877-344-7529
Replay Canada Dial-In Number: 855-669-9658
Replay International Dial-in Number: 412-317-0088
Replay Access Code: 7096297
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.
Stern Investor Relations, Inc.
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.